BeyondSpring (NASDAQ:BYSI) Trading Down 4.2% – Should You Sell?

BeyondSpring Inc. (NASDAQ:BYSI)’s stock price traded down 4.2% during trading on Friday . The company traded as low as $1.81 and last traded at $1.84. 69,525 shares traded hands during trading, a decline of 90% from the average session volume of 716,864 shares. The stock had previously closed at $1.92.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d+)” rating on shares of BeyondSpring in a report on Monday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, BeyondSpring currently has a consensus rating of “Sell”.

BeyondSpring Trading Down 4.2%

The stock has a market cap of $74.21 million, a price-to-earnings ratio of -12.27 and a beta of 0.53. The firm’s 50-day moving average is $1.98 and its two-hundred day moving average is $2.03.

Institutional Trading of BeyondSpring

An institutional investor recently raised its position in BeyondSpring stock. Geode Capital Management LLC raised its position in BeyondSpring Inc. (NASDAQ:BYSI) by 951.4% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 256,212 shares of the company’s stock after purchasing an additional 231,844 shares during the period. Geode Capital Management LLC owned 0.64% of BeyondSpring worth $603,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 40.29% of the company’s stock.

About BeyondSpring

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.